Now, the maker of a once-weekly insulin injection is seeking approval from the U.S. Food and Drug Administration, but a committee of agency advisers is divided on whether the benefits of the product may outweigh the risks.Related video above: High cost makes weight loss, diabetes drugs inaccessibleIn a meeting Friday, the FDA 's Endocrinologic and Metabolic Drugs Advisory Committee weighed whether the benefits of Novo Nordisk's weekly product, called insulin icodec, outweigh its risks.
'This would add a tool to the toolbox for clinicians,' Onumah said.'It will not be beneficial for every person, but it might be useful for some persons,' she said. 'There's still a few risk mitigation things that need to be ironed out clearly so that for the general provider or practitioner who would be writing this prescription, should it be approved, will be doing it correctly and safely – because safety would be very important.'Committee member Dr.
Source: Healthcare Press (healthcarepress.net)
FDA Food And Drug Administration Ozempic Benefits Diabetes Insulin
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: KSLcom - 🏆 549. / 51 Read more »
Source: fox13seattle - 🏆 328. / 59 Read more »
Source: Medscape - 🏆 386. / 55 Read more »
Source: MedicineNet - 🏆 575. / 51 Read more »
Source: WebMD - 🏆 709. / 51 Read more »
Source: CBSNews - 🏆 87. / 68 Read more »